Positron emission tomography and colorectal cancer

Critical Reviews in Oncology/Hematology

Volumn 77, Issue 1, 2011, Pages 30-47

  Lin, Michael ^a,b,c   Wong, Karen ^a,b,c   Ng, Weng Leong ^a,b,c   Shon, Ivan Ho ^a,b   Morgan, Matthew ^c,d  

^a LIVERPOOL HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Sydney South West Area Health Service   (Australia)

^d BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

Author keywords

Colorectal cancer; FDG; Oncology; PET; Positron emission tomography; Therapy response

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CRYOSURGERY; EARLY DIAGNOSIS; HUMAN; LIVER METASTASIS; LIVER RESECTION; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOFREQUENCY ABLATION; RECTUM CANCER; RECTUM SURGERY; RECURRENT CANCER; REVIEW; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE;

COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS;

EID: 78650311121     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.04.011     Document Type: Review

References (167)

1. Van Cutsem E., Oliveira J. Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2009, 20(Suppl. 4):49-50.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics 2009. CA Cancer J Clin 2009, 59:225-249.
3. Lin M., Ho Shon I., Lin P. Positron emission tomography-current status and future challenges. Intern Med J 2010, 40:19-29.
4. Hillner B.E., Siegel B.A., Liu D., et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 2008, 26:2155-2161.
5. Papathanassiou D., Bruna-Muraille C., Liehn J.-C., Nguyen T.D., Curé H. Positron Emission Tomography in oncology: Present and future of PET and PET/CT. Crit Rev Oncol Hematol 2009, 72:239-254.
6. Antoch G., Saoudi N., Kuehl H., et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004, 22:4357-4368.
7. Cohade C., Osman M., Leal J., Wahl R. Direct comparison of 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003, 44:1797-1803.
8. Czernin J., Allen-Auerbach M., Schelbert H. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007, 48:78S-88S.
9. Burt B.M., Humm J.L., Kooby D.A., et al. Using positron emission tomography with [18F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia 2001, 3:189-195.
10. Veit-Haibach P., Kuehle C.A., Beyer T., et al. Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA 2006, 296:2590-2600.
11. Nagata K., Ota Y., Okawa T., Endo S., Kudo S.E. PET/CT colonography for the preoperative evaluation of the colon proximal to the obstructive colorectal cancer. Dis Colon Rectum 2008, 51(6):882-890.
12. Heriot A., Kumar D. Rectal cancer recurrence: factors and mechanisms. Colorectal Dis 2000, 2:126-137.
13. Quirke P., Durdey P., Dixon M.F., Williams N.S. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986, 328(8514):996-999.
14. Adam I.J., Mohamdee M.O., Martin I.G., et al. Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994, 344(8924):707-711.
15. Chan K.W., Boey J., Wong S.K. A method of reporting radial invasion and surgical clearance of rectal carcinoma. Histopathology 1985, 9(12):1319-1327.
16. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 2006, 333(7572):779. MERCURY Study Group.
17. Klessen C., Rogalla P., Taupitz M. Local staging of rectal cancer. The current role of MRI. Eur Radiol 2007, 17:379-389.
18. Bipat S., Glas A.S., Slors F.J.M., Zwinderman A.H., Bossuyt P.M.M., Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging-a meta-analysis. Radiology 2004, 232:773-783.
19. Brown G., Richards C.J., Bourne M.W., et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 2003, 227:371-377.
20. Gearhart S.L., Frassica D., Rosen R., Choti M., Schulick R., Wahl R. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 2006, 13:397-404.
21. Davey K., Heriot A.G., Mackay J., et al. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum 2008, 51:997-1003.
22. Heriot A.G., Hicks R.J., Drummond E.G.P., et al. Does positron emission tomography change management in primary rectal cancer? A prospective assessment. Dis Colon Rectum 2004, 47:451-458.
23. Llamas-Elvira J.M., Rodriguez-Fernandez A., Gutierrez-Sainz J., et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging 2007, 34:859-867.
24. Akiyoshi T., Oya M., Fujimoto Y., et al. Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer. Colorectal Dis 2009, 11:464-469.
25. Eglinton T., Luck A., Bartholomeusz D., Varghese R., Lawrence M. Positron-emission tomography/computed tomography in the initial staging of primary rectal cancer. Colorectal Dis 2010, 12:667-673.
26. Furukawa H., Ikuma H., Seki A., et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut 2006, 55:1007-1011.
27. Tateishi U., Maeda T., Morimoto T., Miyake M., Arai Y., Kim E.E. Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging 2007, 34:1627-1634.
28. Nahas C.S.R., Akhurst T., Yeung H., et al. Positron emission tomography detection of distant metastatic or synchronous disease in patients with locally advanced rectal cancer receiving preoperative chemoradiation. Ann Surg Oncol 2008, 15(3):704-711.
29. Abdel-Nabi H., Doerr R.J., Lamonica D.M., et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998, 206:755-760.
30. Mukai M., Sadahiro S., Yasuda S., et al. Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep 2000, 7:85-87.
31. Kantorova I., Lipska L., Belohlavek O., Visokai V., Trubac M., Schneiderova M. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003, 44:1784-1788.
32. Monig S.P., Baldus S.E., Zirbes T.K., et al. Lymph node size and metastatic infiltration in colon cancer. Ann Surg Oncol 1999, 6(6):579-581.
33. Park I.J., Kim H.C., Yu C.S., et al. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol 2006, 32(9):941-947.
34. Galandiuk S., Wieand H.S., Moertel C.G., et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992, 174:27-32.
35. Salo J.C., Paty P.B., Guillem J., Minsky B.D., Harrison L.B., Cohen A.M. Surgical salvage of recurrent rectal carcinoma after curative resection: a 10 year experience. Ann Surg Oncol 1999, 6:171-177.
36. Tepper J.E., O'Connell M., Hollis D., Niedzwiecki D., Cooke E., Mayer R.J. Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. J Clin Oncol 2003, 21:3623-3628.
37. Fong Y., Fortner J., Sun R.L., Brennan M.F., Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309-318.
38. Wei A.C., Greig P.D., Grant D., Taylor B., Langer B., Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006, 13(5):668-676.
39. Steele G., Bleday R., Mayer R.J., Lindblad A., Petrelli N., Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 1991, 9:1105-1112.
40. Lejeune C., Bismuth M.J., Conroy T., et al. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med 2005, 46:2020-2028.
41. Huebner R.H., Park K.C., Shepherd J.E., et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000, 41:1177-1189.
42. Meta J., Seltzer M., Schiepers C., et al. Impact of 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med 2001, 42:586-590.
43. Kalff V., Hicks R.J., Ware R.E., Hogg A., Binns D., McKenzie A.F. The clinical impact of 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002, 43:492-499.
44. Scott A.M., Gunawardana D.H., Kelley B., et al. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med 2008, 49:1451-1457.
45. National Comprehensive Cancer Network-Clinical Practice Guidelines in Oncology: Colon Cancer, v.1.2009, available at http://www.nccn.org/.
46. Australian Cancer Network Colorectal Cancer Guidelines Revision Committee Guidelines for the prevention, early detection and management of colorectal cancer 2005, The Cancer Council Australia and Australian Cancer Network, Sydney.
47. Yonekura Y., Benua R.S., Brill A.B., et al. Increased accumulation of 2-deoxy-2-[18F]Fluoro-d-glucose in liver metastases from colon carcinoma. J Nucl Med 1982, 23:1133-1137.
48. Wiering B., Krabbe P.F.M., Jager G.J., Oyen W.J.G., Ruers T.J.M. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005, 104:2658-2670.
49. Bipat S., van Leeuwen M.S., Comans E.F.I., et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 2005, 237:123-131.
50. Kong G., Jackson C., Koh D.M., et al. The use of (18)F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008, 35:1323-1329.
51. Schussler-Fiorenza C.M., Mahvi D.M., Niederhuber J., Rikkers L.F., Weber S.M. Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases. J Gastrointest Surg 2004, 8:150-158.
52. Coenegrachts K., De Geeter F., ter Beek L., et al. Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases. Eur Radiol 2009, 19:370-379.
53. Strasberg S.M., Dehdashti F., Siegel B.A., Drebin J.A., Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001, 233:293-299.
54. Fernandez F.G., Drebin J.A., Linehan D.C., Dehdashti F., Siegel B.A., Strasberg S.M. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004, 240:438-447.
55. Pawlik T.M., Assumpcao L., Vossen J.A., et al. Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases. Ann Surg Oncol 2009, 16:371-378.
56. Ruers T.J.M., Wiering B., van der Sijp J.R.M., et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with 18F-FDG PET: a randomized study. J Nucl Med 2009, 50:1036-1041.
57. Finkelstein S.E., Fernandez F.G., Dehdashti F., et al. Unique site- and time-specific patterns of recurrence following resection of colorectal carcinoma hepatic metastases in patients staged by FDG-PET. J Hepatobiliary Pancreat Surg 2008, 15:483-487.
58. Riedl C.C., Akhurst T., Larson S., et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 2007, 48:771-775.
59. de Geus-Oei L.F., Wiering B., Krabbe P.F., Ruers T.J.M., Punt C.J.A., Oyen W.J.G. FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Ann Oncol 2006, 17:1650-1655.
60. Scheer M.G.W., Stollman T.H., Vogel W.V., Boerman O.C., Oyen W.J.G., Ruers T.J.M. Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. J Nucl Med 2008, 49:887-891.
61. Beets G., Penninckx F., Schiepers C., et al. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994, 81:1666-1670.
62. Strauss L.G., Corius J.H., Schlag P., et al. Recurrence of colorectal tumours: PET evaluation. Radiology 1989, 170:329-332.
63. Ito K., Kato T., Tadokoro M., et al. Recurrent rectal cancer and scar differentiation with PET and MR imaging. Radiology 1992, 182:549-552.
64. Whiteford M.H., Whiteford H.M., Yee L.F., et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000, 43:759-767.
65. Flamen P., Stroobants S., Van Cutsem E., et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-d-glucose in recurrent colorectal cancer. J Clin Oncol 1999, 17:894-901.
66. Lonneux M., Reffad A.M., Detry R., Kartheuser A., Gigot J.F., Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2002, 29:915-921.
67. Even-Sapir E., Parag Y., Lerman H., et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004, 232:815-822.
68. Votrubova J., Belohlavek O., Jaruskova M., et al. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 2006, 33:779-784.
69. Kitajima K., Murakami K., Yamasaki E., et al. Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging 2009, 36:1388-1396.
70. Minton J.P., Hoehn J.L., Gerber D.M., et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985, 55:1284-1290.
71. Ruhlmann J., Schomburg A., Bender H., et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 1997, 40:1195-1204.
72. Zervos E.E., Badgwell B.D., Burak W.E., Arnold M.W., Martin E.W. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery 2001, 130:636-643.
73. Flanagan F.L., Dehdashti F., Ogunbiyi O.A., Kodner I.J., Siegel B.A. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998, 227:319-323.
74. Liu F.Y., Chen J.S., Changchien C.R., et al. Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels. Dis Colon Rectum 2005, 48:1900-1912.
75. Choi M.Y., Lee K.M., Chung J.K., et al. Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer. Ann Nucl Med 2005, 19(2):123-129.
76. Sarikaya I., Bloomston M., Povoski S.P., et al. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World J Surg Oncol 2007, 5:64.
77. Tanaka T., Kawai Y., Kanai M., Taki Y., Nakamoto Y., Takabayashi A. Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of colorectal cancer. Am J Surg 2002, 184:433-436.
78. Dromain C., Leboulleux S., Auperin A., et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging 2007, 33:87-93.
79. De Gaetano A.M., Calcagni M.L., Rufini V., Valenza V., Giordano A., Bonomo L. Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. Abdom Imaging 2009, 34(3):391-402.
80. Dirisamer A., Schima W., Heinisch M., et al. Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT. Eur J Radiol 2009, 69:536-541.
81. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
82. Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(Suppl. 1):122S-150S.
83. Guillem J.G., Puig-La Calle J., Akhurst T., et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluordeoxyglucose positron emission tomography. Dis Colon Rectum 2000, 43:18-24.
84. Amthauer H., Denecke T., Rau B., et al. Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 2004, 31(6):811-819.
85. Denecke T., Rau B., Hoffmann K.T., et al. Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging?. Eur Radiol 2005, 15:1658-1666.
86. Melton G.B., Lavely W.C., Jacene H.A., et al. Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg 2007, 11:961-969.
87. Vliegen R.F., Beets-Tan R.G., Vanhauten B., et al. Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer?. Strahlenther Onkol 2008, 184:457-464.
88. Konski A., Li T., Sigurdson E., et al. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys 2009, 74(1):55-59.
89. Cascini G.L., Avallone A., Delrio P., et al. 18 F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 2006, 47:1241-1248.
90. Capirci C., Rubello D., Chierichetti F., et al. Long-term prognostic value of 18F-FDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant radiochemotherapy. Am J Roentgenol 2006, 187:202-208.
91. Kalff V., Duong C., Drummond E.G., Matthews J.P., Hicks R.J. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med 2006, 47:14-22.
92. Kalff V., Ware R., Heriot A., Chao M., Drummond E., Hicks R.J. Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy. Int J Radiation Oncology Biol Phys 2009, 74(1):60-66.
93. Chau I., Cunningham D. Treatment in advanced colorectal cancer: what, when and how?. Br J Cancer 2009, 100:1704-1719.
94. Goshen E., Davidson T., Zwas S.T., Aderka D. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat 2006, 5:37-43.
95. Strauss L.G., Koczan D., Klippel S., et al. Impact of angiogenesis-related gene expression on the tracer kinetics of 18F-FDG in colorectal tumors. J Nucl Med 2008, 49:1238-1244.
96. Akhurst T., Kates T.J., Mazumdar M., et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005, 23:8713-8716.
97. Lubezky N., Metser U., Geva R., et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007, 11:472-478.
98. Tan M.C., Linehan D.C., Hawkins W.G., Siegel B.A., Strasberg S.M. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007, 11:1112-1119.
99. Adie S., Yip C., Chu F., Morris D.L. Resection of liver metastases from colorectal cancer: does preoperative chemotherapy affect the accuracy of PET in preoperative planning?. ANZ J Surg 2009, 79:358-361.
100. Takahashi S., Kuroki Y., Nasu K., et al. Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy. Anticancer Res 2006, 26:4705-4711.
101. Small R.M., Lubezky N., Shmueli E., et al. Response to chemotherapy predicts survival following resection of hepatic colorectal metastases in patients treated with neoadjuvant therapy. J Surg Oncol 2009, 99:93-98.
102. Findlay M., Young H., Cunningham D., et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996, 14:700-708.
103. Bender H., Bangard N., Metten N., et al. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. Hybridoma 1999, 18:87-91.
104. Dimitrakopoulou-Strauss A., Strauss L.G., Burger C., et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 2004, 45:1480-1487.
105. Dimitrakopoulou-Strauss A., Strauss L.G., Rudi J. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q J Nucl Med 2003, 47:8-13.
106. de Geus-Oei L.F., van Laarhoven H.W., Visser E.P., et al. Chemotherapy response evaluation with FDG PET in patients with colorectal cancer. Ann Oncol 2007, 19:348-352.
107. Young H., Baum R., Cremerius U., et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35:1773-1782.
108. Bystrom P., Berglund A., Garske U., et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 2009, 20:1057-1062.
109. Langenhoff B.S., Oyen W.J., Jager G.J., et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002, 20:4453-4458.
110. Donckier V., Van Laethem J.L., Goldman S., et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 2003, 84:215-223.
111. Anderson G.S., Brinkmann F., Soulen M.C., Alavi A., Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003, 28:192-197.
112. Joosten J., Jager G., Oyen W., Wobbes T., Ruers T. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol 2005, 31:1152-1159.
113. Blokhuis T.J., van der Schaaf M.C., van den Tol M.P., Comans E.F.I., Manoliu R.A., van der Sijp J.R. Results of radio frequency ablation of primary and secondary liver tumors: long-term follow-up with computed tomography and positron emission tomography-18F-deoxyfluoroglucose scanning. Scand J Gastroenterol (Suppl) 2004, 241:93-97.
114. Veit P., Antoch G., Stergar H., Bockisch A., Forsting M., Kuehl H. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol 2006, 16:80-87.
115. Travaini L., Trifiro G., Ravasi L., et al. Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results. Eur J Nucl Med Mol Imaging 2008, 35:1316-1322.
116. Barker D.W., Zagoria R.J., Morton K.A., Kavanagh P.V., Shen P. Evaluation of liver metastases after radiofrequency ablation: Utility of 18F-FDG PET and PET/CT. Am J Roentgenol 2005, 184(4):1096-1102.
117. Kuehl H., Antoch G., Stergar H., et al. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: Initial results. Eur J Radiol 2008, 67:362-371.
118. Khandani A.H., Calvo B.F., O'Neil B.H., Jorgenson J., Mauro M.A. A pilot study of early 18F-FDG PET to evaluate the effectiveness of radiofrequency ablation of liver metastases. Am J Roentgenol 2007, 189:1199-1202.
119. Denecke T., Steffen I., Hildebrandt B., et al. Assessment of local control after laser-induced thermotherapy of liver metastases from colorectal cancer: contribution of FDG-PET in patients with clinical suspicion of progressive disease. Acta Radiol 2007, 48:821-830.
120. Avril N. 18F-FDG PET after radiofrequency ablation: is timing everything?. J Nucl Med 2006, 47:1235-1237.
121. Wong C.Y., Salem R., Raman S., Gates V.L., Dworkin H.J. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002, 29:815-820.
122. Popperl G., Helmberger T., Munzing W., Schmind R., Jacobs T.F., Tasch K. Selective internal radiation therapy with SIR-spheres in patients with nonresectable liver tumours. Cancer Biother Radiopharm 2005, 20:200-208.
123. Lin M., Shon I.H., Wilson R., D'Amours S.K., Schlaphoff G., Lin P. Treatment response in liver metastases following 90Y SIR-spheres: an evaluation with PET. Hepatogastroenterology 2007, 54:910-912.
124. Biernert M., McCook B., Carr B.I., et al. 90Y microsphere treatment of unresectable liver metastases: changes in the FDG uptake and tumor size on PET-CT. Eur J Nucl Med Mol Imaging 2005, 32:778-787.
125. Szyszko T., Al-Nahhas A., Canelo R., et al. Assessment of response to treatment of unresectable liver tumours with Y90 microspheres: Value of FDG-PET versus computed tomography. Nucl Med Commun 2007, 28:15-20.
126. Wong C.Y., Salem R., Qing F., et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 2004, 45:1892-1897.
127. Wong C.Y., Qing F., Savin M., et al. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 2005, 16:1101-1106.
128. Flamen P., Vanderlinden B., Delatte P., et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. Phys Med Biol 2008, 53:6591-6603.
129. Gregoire V., Haustermans K., Geets X., Roels S., Lonneux M. PET-based treatment planning in radiotherapy: a new standard?. J Nucl Med 2007, 48:68-77S.
130. Ciernik I.F., Dizendorf E., Baumert B.G., et al. Radiation treatment planning with an integrated Positron Emission and Computer Tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003, 57:853-863.
131. Ciernik I.F., Huser M., Burger C., Davis J.B., Szekely G. Automated functional image-guided radiation treatment planning for rectal cancer. Int J Radiat Oncol Biol Phys 2005, 62:893-900.
132. Patel D.A., Chang S.T., Goodman K.A., et al. Impact of integrated PET/CT on variability of target volume delineation in rectal cancer. Technol Cancer Res Treat 2007, 6:31-36.
133. Anderson C., Koshy M., Staley C., et al. PET-CT fusion in radiation management of patients with anorectal tumors. Int J Radiat Oncol Biol Phys 2007, 69:155-162.
134. Bassi M.C., Turri L., Sacchetti G., et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 2008, 70:1423-1426.
135. Paskeviciute B., Bölling T., Brinkmann M., et al. Impact of 18F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancer. Strahlenther Onkol 2009, 185:260-265.
136. Roels S., Slagmolen P., Nuyts J., et al. Biological image-guided radiotherapy in rectal cancer: Is there a role for FMISO or FLT, next to FDG?. Acta Oncol 2008, 47:1237-1248.
137. Roels S., Slagmolen P., Nuyts J., et al. Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls. Int J Radiat Oncol Biol Phys 2009, 75:782-790.
138. Li Destri G., Di Cataldo A., Puleo S. Colorectal cancer follow-up: useful or useless?. Surg Oncol 2006, 15:1-12.
139. Goldberg R.M., Fleming T.R., Tangen C.M., et al. Surgery for recurrent colon cancer:strategies for identifying resectable recurrence and success rates after resection. Eastern Cooperative Oncology Group, the North Central Cancer Treatment Group, and the Southwest Oncology Group. Ann Intern Med 1998, 129:27-35.
140. Abgral R., Querellou S., Potard G., et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up?. J Nucl Med 2009, 50:24-29.
141. Brooks R.A., Rader J.S., Dehdashti F., et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol 2009, 112:104-109.
142. Selvaggi F., Cuocolo A., Sciaudone G., Maurea S., Giuliani A., Mainolfi C. FGD-PET in the follow-up of recurrent colorectal cancer. Colorectal Dis 2003, 5:496-500.
143. Sobhani I., Tiret E., Lebtahi R., et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 2008, 98(5):875-880.
144. Lieberman D. Colon cancer screening and surveillance controversies. Curr Opin Gastroenterol 2009, 25(5):422-427.
145. Yasuda S., Shohtsu A. Cancer screening with whole-body 18F-fluorodeoxyglucose positron-emission tomography. Lancet 1997, 350:1819.
146. Yasuda S., Fujii H., Nakahara T., et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med 2001, 42:989-992.
147. Kojima S., Zhou B., Teramukai S., et al. Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: The Nishidai clinic study. Eur J Cancer 2007, 43:1842-1848.
148. Terauchi T., Murano T., Daisaki H., et al. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-d-glucose positron emission tomography: a preliminary report. Ann Nucl Med 2008, 22:379-385.
149. Minamimoto R., Senda M., Uno K., et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med 2007, 21:481-491.
150. Nishizawa S., Kojima S., Teramukai S., et al. Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]Fluorodeoxyglucose Positron Emission Tomography in a healthy population: a preliminary report. J Clin Oncol 2009, 27:1767-1773.
151. Beatty J.S., Williams H.T., Aldridge B.A., et al. Incidental PET/CT findings in the cancer patient: how should they be managed?. Surgery 2009, 146(2):274-281.
152. Hillman B.J. Screening for cancer with high technology imaging tests. J Clin Oncol 2009, 27:1740-1741.
153. Kamel E.M., Thumshirn M., Truninger K., et al. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 2004, 45:1804-1810.
154. Agress H., Cooper B.Z. Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. Radiology 2004, 230:417-422.
155. Israel O., Yefremov N., Bar-Shalom R., et al. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med 2005, 46:758-762.
156. Even-Sapir E., Lerman H., Gutman M., et al. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 2006, 33:541-552.
157. Van Kouwen M.C.A., Nagengast F.M., Jansen J.B.M.J., Oyen W.J.G., Drenth J.P.H. 2-(18F)-fluoro-2-deoxy-d-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol 2005, 23:3713-3717.
158. Gutman F., Alberini J.-L., Wartski M., et al. Incidental colonic focal lesions detected by FDG PET/CT. Am J Roentgenol 2005, 185:495-500.
159. Hemandas A.K., Robson N.K., Hickish T., Talbot R.W. Colorectal tubulovillous adenomas identified on fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scans. Colorectal Dis 2008, 10(4):386-389.
160. Lee S.T., Tan T., Poon A.M.T., et al. Role of low-dose, noncontrast computed tomography from integrated positron emission tomography/computed tomography in evaluating incidental 2-deoxy-2-[F-18]fluoro-d-glucose-avid colon lesions. Mol Imaging Biol 2008, 10(1):48-53.
161. Lee J.C., Hartnett G.F., Hughes B.G.M., Ravi Kumar A.S. The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT. Nucl Med Commun 2009, 30:333-337.
162. Schlemmer H.P.W., Pichler B.J., Schmand M., et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology 2008, 248(3):1028-1035.
163. Giesel F.L., Mehndiratta A., Locklin J., et al. Exp Oncol 2009, 31:106-114.
164. Cherry S.R. Multimodality imaging: beyond PET/CT and SPECT/CT. Semin Nucl Med 2009, 39:348-353.
165. Wieder H.A., Geinitz H., Rosenberg R., et al. PET imaging with [18F]3'-deoxy-3'-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 2007, 34:878-883.
166. Wieder H., Ott K., Zimmermann F., et al. PET imaging with [11C]methyl-l-methionine for therapy monitoring in patients with rectal cancer. Eur J Nucl Med 2002, 29:789-796.
167. Dietz D.W., Dehdashti F., Grigsby P.W., et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Col Rectum 2008, 51:1641-1648.